Julie R. Gralow, MD

Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, clinical research division, member, Fred Hutchinson Cancer Care Center, professor, Medical Oncology Division, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.

compared the toxicities and patient-stated preferences for oral versus IV delivery of 3 bisphosphonates: clodronate, ibandronate, and zoledronic acid.

76% of patients preferred receiving bisphosphonates orally as opposed to IV.

There are no good data on oral bisphosphonates with respect to breast cancer recurrence.

There remains a need to understand what tumor factors might predict for who benefits from bisphosphonates.

Studies are ongoing looking at potential impact of denosumab on recurrence.

Videos

Julie R. Gralow, MD, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Care Center, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.

Future Research Into Bisphosphonates in Breast Cancer

Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.

Articles

Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.

Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial

Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, clinical research division, member, Fred Hutchinson Cancer Care Center, professor, Medical Oncology Division, University of Washington School of Medicine, gives an overview of a phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer.

The only chemotherapy that was given during the phase II trial was 12 weeks of weekly paclitaxel, which was followed by 9 months of trastuzumab

The only death that occurred was from ovarian cancer

Based on the findings of this study, physicians are wondering if patients with tumors of < 1 cm even need chemotherapy, especially if they are ER+

Julie R. Gralow, MD, gives an overview of a phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer.

Julie R. Gralow, MD | Authors

Articles

Future Research Into Bisphosphonates in Breast Cancer

Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial

An Analysis of the APT Trial